VistaGen Therapeutics, Inc. (VTGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. NV
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,62216,63825,03735,28751,98668,135
Cash and cash equivalents9,62216,63825,03735,28751,98668,135
Capitalized contract cost 67 6767117 
Deferred costs67676767117117
Other undisclosed current assets1,8228038861,4932,7732,746
Total current assets:11,57917,50726,05836,91454,99470,998
Noncurrent Assets
Operating lease, right-of-use asset2,1542,2602,3642,4662,5652,662
Property, plant and equipment476507541559568414
Capitalized contract cost, net 201 234251117 
Deposits noncurrent assets101101101101101101
Deferred costs201218234251117146
Other undisclosed noncurrent assets321496177160264322
Total noncurrent assets:3,4543,5823,6513,7883,7323,645
TOTAL ASSETS:15,03221,08929,70940,70258,72674,643
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,0483,2612,6844,4576,4414,154
Employee-related liabilities31124166
Accounts payable1,6232,4731,5992,9585,4732,759
Accrued liabilities4257871,0851,1887271,329
Deferred revenue7147147127121,2441,244
Debt22222 
Other undisclosed current liabilities1,2855918908751,240367
Total current liabilities:4,0494,5674,2876,0458,9265,765
Noncurrent Liabilities
Long-term debt and lease obligation7782,3802,5002,605
Finance lease, liability77889 
Liabilities, other than long-term debt4,1274,4344,7392,6721,2481,558
Deferred revenue2,1372,3152,4922,6721,2481,558
Operating lease, liability1,9902,1202,2472,3712,4912,605
Total noncurrent liabilities:4,1344,4424,7475,0513,7474,163
Total liabilities:8,1839,0099,03411,09712,6749,928
Equity
Equity, attributable to parent, including:6,84912,08020,67529,60546,05264,715
Common stock87207207 207
Treasury stock, value(3,968)(3,968)(3,968)(3,968)(3,968)(3,968)
Additional paid in capital344,564342,893339,060338,230337,194336,081
Accumulated deficit(333,755)(326,852)(314,625)(304,864)(287,380)(267,604)
Other undisclosed equity, attributable to parent     207 
Total equity:6,84912,08020,67529,60546,05264,715
TOTAL LIABILITIES AND EQUITY:15,03221,08929,70940,70258,72674,643

Income Statement (P&L) ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
Revenues (227)  310461
Gross profit:    310461
Operating expenses(7,175)(12,415)(9,946)(16,597)(20,083)(36,525)
Other undisclosed operating income (loss) 178176180(893) (0)
Operating loss:(6,998)(12,239)(9,767)(17,489)(19,773)(36,064)
Other undisclosed income from continuing operations before equity method investments, income taxes      6
Loss from continuing operations before equity method investments, income taxes:(6,998)(12,239)(9,767)(17,489)(19,773)(36,058)
Other undisclosed income from continuing operations before income taxes971356220
Loss from continuing operations before income taxes:(6,901)(12,227)(9,761)(17,483)(19,771)(36,038)
Income tax expense (3)(0)  (6)(1)
Loss from continuing operations:(6,903)(12,227)(9,761)(17,483)(19,776)(36,039)
Loss before gain (loss) on sale of properties:(17,483)(19,776)(36,039)
Net loss attributable to parent:(6,903)(12,227)(9,761)(17,483)(19,776)(36,039)
Preferred stock dividends and other adjustments      92
Net loss available to common stockholders, diluted:(6,903)(12,227)(9,761)(17,483)(19,776)(35,948)

Comprehensive Income ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
Net loss:(6,903)(12,227)(9,761)(17,483)(19,776)(36,039)
Comprehensive loss, net of tax, attributable to parent:(6,903)(12,227)(9,761)(17,483)(19,776)(36,039)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: